APG Asset Management US’s Biogen BIIB Stock Holding History

APG Asset Management US’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,010	Closed	-$464K	–	72
2025 Q3	$464K	Hold	3,010	–	–	﹤0.01%	164
2025 Q2	$392K	Hold	3,010	–	–	﹤0.01%	169
2025 Q1	$397K	Hold	3,010	–	–	﹤0.01%	173
2024 Q4	$460K	Buy	+3,010	New	+$508K	﹤0.01%	170

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

APG Asset Management US's BIIB Position: Q4 2025 in Review

APG Asset Management US sold out of Biogen (BIIB) in Q4 2025, closing a stake of 3,010 shares — an estimated $464K sold.

APG Asset Management US first reported a position in BIIB in Q4 2024 and held it in 4 quarters. The position peaked at $464K in Q3 2025. 1,000 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

APG Asset Management US reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
APG Asset Management US sold 3,010 Biogen shares in Q4 2025, an estimated $464K.
APG Asset Management US first reported a position in Biogen in Q4 2024 and held it in 4 quarters.
APG Asset Management US's Biogen position peaked at $464K in Q3 2025.
1,000 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on APG Asset Management US's 13F filing for Q4 2025, filed 12 Feb 2026.